Leading companies in the burn market include Medical Developments International, Cumberland Pharmaceuticals, Janssen Research and Development, and Cephalon.
DelveInsight's latest report,“Burns Market Insights, Epidemiology, and Market Forecasts – 2034”provides a comprehensive analysis of burn injuries with detailed insights into historical and projected epidemiological trends, market dynamics, and treatment status in the US, EU4 (Germany, Spain, Italy, France, UK), and Japan.
Click here to explore insights into burn market outlook, treatment trends, drug intake, and epidemiology. Burn pain market forecast
Key highlights of the burns market report:
- The burn pain market is projected to expand at a significant CAGR during the forecast period (2020-2034).
- In August 2024, MediWound Ltd. (Nasdaq: MDWD) received FDA approval for NexoBrid® (anacaulase-bcdb) for scab removal in pediatric patients with deep-segment and full-thickness burns from neonates to 18 years of age. This is a major milestone as NexoBrid has been approved for all age groups in the US, similar to its approval in the EU and Japan.
- The US led the market in 2023 with a valuation of $140 million and is expected to maintain its dominance until 2034.
- Within the EU4, Germany and the UK will have a market size of over $20 million in 2023, followed by France. Italy recorded the lowest market share in the region during the same period.
- Opioid analgesics dominate current treatment practice in both inpatient and outpatient settings, with a market value estimated at USD 130 million in 2023.
- More than 2 million burn incidents will be reported in the United States in 2023, and this number is expected to increase by 2034.
- Approximately 400,000 burn cases requiring pain management will be recorded in the United States in 2023, with changes expected over the forecast period.
- The majority of burn pain cases in 7MM are male patients, and in 2023, the number of male patients will be approximately 290,000 and the number of female patients will be approximately 260,000.
Treatment of major burns include methoxyflurane (PENTHROX), Caldolor, JNJ-42160443, and ACTIQ.
Burns Market Segmentation by Etiology Includes flame, contact, burns, electricity, chemistry, and more.
The burn injury market is poised for growth due to the rising prevalence and awareness of the disease, as well as the anticipated launch of multiple pipeline products that will significantly change market trends.
Overview of burn pain
Burns are damage to organic tissue primarily caused by heat sources, electricity, radiation, chemicals, friction, or radioactivity.
Get a free sample of Burn Pain Market Report now:
https://www.delveinsight.com/sample-request/burn-pain-market
Epidemiology of burn injuries
This section explores past, current, and projected trends in burn epidemiology over 7MM from 2020 to 2034, based on key studies and expert insights. It also includes a detailed breakdown of the diagnosed patient population and expected future trends.
Epidemiology segmentation of burn pain includes:
- Total burn prevalence
- Epidemic cases by severity
- Prevalence by gender
- Diagnosed episodic and chronic cases
Download the report to see what factors are shaping burn epidemiology trends. Prediction of epidemiology of burn injuries
Pharmaceutical intake and pipeline development
This section provides an overview of the uptake of existing and upcoming treatments in the burn area, including patient recruitment, drug sales, and competitive analysis.
A review of the therapeutic landscape will help identify the fastest growing drugs and explain their widespread use. It also benchmarks drugs based on market share and uptake.
Additionally, the report covers development activities across all stages of new burn treatments, including strategic alliances, licensing, and mergers.
Main burn treatments and developers
- Methoxyflurane (PENTHROX) – Medical Development International
- Kaldor – Cumberland Pharmaceuticals
- JNJ-42160443 – Janssen Research and Development
- actic – Cephalon
Find out which treatments are expected to lead the burns market. Burn treatment market
Market strengths and opportunities
Strengths:
The rising incidence of burn injuries is expected to drive demand for treatment and open up new market opportunities.
opportunity:
The growing need for drug treatments for burn pain represents a potentially lucrative opportunity for emerging pharmaceutical companies.
Scope of Burns Market Report
- Study period: 2020 ~ 2034
- coverage: 7MM (US, EU5, Japan)
- Major companies: Medical Developments International、Cumberland Pharmaceuticals、Janssen R&D、Cephalon など
- Main treatments: Methoxyflurane (PENTHROX), Caldolol, JNJ-42160443, ACTIQ, etc.
- Evaluation includes: Commercial and Pipeline Therapies, Market Drivers and Barriers
- Analysis tools: SWOT, PESTLE, BCG Matrix, Porter's Five Forces
- Additional coverage: Unmet needs, KOL insights, access and reimbursement landscape
For more information about companies in this field, please visit: Burn clinical trials and treatment evaluation
table of contents
- introduction
- executive summary
- SWOT analysis
- Patient Share Overview
- Market overview
- Background of the disease
- epidemiology and population
- Number of patients by country
- current treatments
- unmet needs
- new treatment
- market outlook
- Market forecast for each country
- Access and refunds
- market drivers
- market barriers
- appendix
- methodology
- DelveInsight features
- Disclaimer
- About DelveInsight
About DelveInsight
DelveInsight is a leading healthcare consulting and market research firm focused on life sciences. We support pharmaceutical companies by providing customized end-to-end solutions to improve business performance. The company also provides strategic healthcare consulting services to help accelerate market entry and overcome operational challenges.
Contact information
Name: Kanishk
Email: kkumar@delveinsight.com
English
Dutch